MAGE-A1-specific TCR / Shennon Biotechnologies - LARVOL DELTA

Discovery and characterization of MAGE-A1-specific TCR candidates for TCR-based cancer therapy (SITC 2025) - "The lead TCRs achieved efficient tumor control both in vitro and in vivo without additional affinity optimization, and were therefore advanced as candidates for the development of TCR-based therapies targeting MAGE-A1+ cancers in HLA-A*03:01+patients.Ethics Approval Patient samples and the patient-derived melanoma tumor cell line were collected under IRB # 15781 and IRB # 10958 of University of Virginia. Animal studies were performed following protocols approved by AAALAC and IACUC."

IO biomarker • Melanoma • Oncology • Solid Tumor • CD69 • HLA-A • IFNG • IL2 • IL2RA • TNFRSF9